Sub Heading

Clinical Trials Details

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

IRB Protocol Number
SZCT-2020-06

Clinical Trial Categories

  • Lung Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: 

  • Locally advanced or metastatic non small cell lung cancer
  • Must have one of the following EGFR mutations: L861Q, G719X, and/or S768I

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.